Research ArticleCystic Fibrosis
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
- Deborah M. Cholon1,
- Nancy L. Quinney1,
- M. Leslie Fulcher1,
- Charles R. Esther Jr.1,2,
- Jhuma Das3,
- Nikolay V. Dokholyan3,
- Scott H. Randell1,4,5,
- Richard C. Boucher1,4 and
- Martina Gentzsch1,5,*
- 1Marsico Lung Institute/Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- 2Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- 3Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- 4Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- 5Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- ↵*Corresponding author. E-mail: gentzsch{at}med.unc.edu
See allHide authors and affiliations
Science Translational Medicine 23 Jul 2014:
Vol. 6, Issue 246, pp. 246ra96
DOI: 10.1126/scitranslmed.3008680
